Literature DB >> 9989994

Malaria vaccines.

A A Holder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9989994      PMCID： PMC33549          DOI： 10.1073/pnas.96.4.1167

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  27 in total

1.  Gamma-globulin and acquired immunity to human malaria.

Authors:  S COHEN; I A McGREGOR; S CARRINGTON
Journal:  Nature       Date:  1961-11-25       Impact factor: 49.962

2.  Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins.

Authors:  B Knapp; E Hundt; B Enders; H A Küpper
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  A hybrid gene to express protein epitopes from both sporozoite and merozoite surface antigens of Plasmodium falciparum.

Authors:  A A Holder; M J Lockyer; G W Hardy
Journal:  Parasitology       Date:  1988-12       Impact factor: 3.234

4.  Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria.

Authors:  R F Anders
Journal:  Parasite Immunol       Date:  1986-11       Impact factor: 2.280

5.  Sequencing the genome of Plasmodium falciparum.

Authors:  D J Carucci; M J Gardner; H Tettelin; L M Cummings; H O Smith; M D Adams; J C Venter; S L Hoffman
Journal:  Curr Opin Infect Dis       Date:  1998-10       Impact factor: 4.915

6.  Merozoite vaccination against Plasmodium knowlesi malaria.

Authors:  G H Mitchell; G A Butcher; S Cohen
Journal:  Immunology       Date:  1975-08       Impact factor: 7.397

7.  A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

Authors:  M E Patarroyo; R Amador; P Clavijo; A Moreno; F Guzman; P Romero; R Tascon; A Franco; L A Murillo; G Ponton
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

8.  Evaluation of 5.1-[NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults.

Authors:  D Stürchler; M Just; R Berger; R Reber-Liske; H Matile; H Etlinger; B Takacs; C Rudin; M Fernex
Journal:  Trop Geogr Med       Date:  1992-01

9.  Plasmodium falciparum: elicitation by peptides and recombinant circumsporozoite proteins of circulating mouse antibodies inhibiting sporozoite invasion of hepatoma cells.

Authors:  M R Hollingdale; W R Ballou; S B Aley; J F Young; S Pancake; L H Miller; W T Hockmeyer
Journal:  Exp Parasitol       Date:  1987-06       Impact factor: 2.011

10.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes.

Authors:  H Bouharoun-Tayoun; P Attanath; A Sabchareon; T Chongsuphajaisiddhi; P Druilhe
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307
View more
  15 in total

1.  Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

Authors:  Jiraprapa Wipasa; Huji Xu; Morris Makobongo; Michelle Gatton; Anthony Stowers; Michael F Good
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response.

Authors:  P V Lalitha; Lisa A Ware; Arnoldo Barbosa; Sheetij Dutta; J Kathleen Moch; J David Haynes; Bader B Fileta; Charles E White; David E Lanar
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

3.  Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites.

Authors:  Dongmei Zhang; Weiqing Pan
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Specificity of the protective antibody response to apical membrane antigen 1.

Authors:  A N Hodder; P E Crewther; R F Anders
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.

Authors:  J C Lima-Junior; J Jiang; R N Rodrigues-da-Silva; D M Banic; T M Tran; R Y Ribeiro; V S E Meyer; S G De-Simone; F Santos; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

6.  Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.

Authors:  Edwin A M Lee; Dupeh R Palmer; Katie L Flanagan; William H H Reece; Kennedy Odhiambo; Kevin Marsh; Margaret Pinder; Michael B Gravenor; Wendy A Keitel; Kent E Kester; Carter Diggs; David Kaslow; V Apostolopoulos; W Ripley Ballou; Adrian V S Hill; Urszula Krzych; Magdalena Plebanski
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice.

Authors:  Zhong Su; Mi-Fong Tam; Dragana Jankovic; Mary M Stevenson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect against Plasmodium yoelii malaria.

Authors:  Kerrianne Mello; Thomas M Daly; Carole A Long; James M Burns; Lawrence W Bergman
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Induction of mosquitocidal activity in mice immunized with Anopheles gambiae midgut cDNA.

Authors:  B D Foy; T Magalhaes; W E Injera; I Sutherland; M Devenport; A Thanawastien; D Ripley; L Cárdenas-Freytag; J C Beier
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya.

Authors:  Indu Malhotra; Arlene Dent; Peter Mungai; Alex Wamachi; John H Ouma; David L Narum; Eric Muchiri; Daniel J Tisch; Christopher L King
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.